share_log

Returns On Capital At China Resources Medical Holdings (HKG:1515) Have Hit The Brakes

Returns On Capital At China Resources Medical Holdings (HKG:1515) Have Hit The Brakes

華潤醫療控股(HKG: 1515)的資本回報率已經下降
Simply Wall St ·  02/16 20:00

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. However, after briefly looking over the numbers, we don't think China Resources Medical Holdings (HKG:1515) has the makings of a multi-bagger going forward, but let's have a look at why that may be.

如果你在尋找下一款多功能裝袋機時不確定從哪裏開始,那麼你應該留意一些關鍵趨勢。除其他外,我們希望看到兩件事;首先,成長 返回 論資本使用率(ROCE),其次是公司的擴張 金額 所用資本的比例。歸根結底,這表明這是一家以不斷提高的回報率對利潤進行再投資的企業。但是,在簡短地查看了這些數字之後,我們認爲華潤醫療控股(HKG: 1515)在未來不具備多袋公司的實力,但讓我們來看看爲什麼會這樣。

Understanding Return On Capital Employed (ROCE)

了解資本使用回報率 (ROCE)

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. The formula for this calculation on China Resources Medical Holdings is:

對於那些不知道的人來說,ROCE是衡量公司年度稅前利潤(其回報率)的指標,相對於該業務使用的資本。華潤醫療控股的計算公式爲:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

已動用資本回報率 = 息稅前收益 (EBIT) ¥(總資產-流動負債)

0.071 = CN¥636m ÷ (CN¥19b - CN¥9.6b) (Based on the trailing twelve months to June 2023).

0.071 = 6.36億元人民幣 ÷(19億元人民幣-96億元人民幣) (基於截至 2023 年 6 月的過去十二個月)

Thus, China Resources Medical Holdings has an ROCE of 7.1%. Ultimately, that's a low return and it under-performs the Healthcare industry average of 11%.

因此,華潤醫療控股的投資回報率爲7.1%。歸根結底,這是一個低迴報,其表現低於醫療保健行業11%的平均水平。

roce
SEHK:1515 Return on Capital Employed February 17th 2024
SEHK: 1515 2024 年 2 月 17 日動用資本回報率

In the above chart we have measured China Resources Medical Holdings' prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free report for China Resources Medical Holdings.

在上圖中,我們將華潤醫療控股先前的投資回報率與之前的表現進行了對比,但可以說,未來更爲重要。如果你想了解分析師對未來的預測,你應該查看我們的華潤醫療控股免費報告。

What Does the ROCE Trend For China Resources Medical Holdings Tell Us?

華潤醫療控股的投資回報率趨勢告訴我們什麼?

There are better returns on capital out there than what we're seeing at China Resources Medical Holdings. The company has consistently earned 7.1% for the last five years, and the capital employed within the business has risen 49% in that time. Given the company has increased the amount of capital employed, it appears the investments that have been made simply don't provide a high return on capital.

那裏的資本回報比我們在華潤醫療控股看到的要好。在過去五年中,該公司的收入一直爲7.1%,在此期間,公司內部使用的資本增長了49%。鑑於該公司增加了動用資本金額,看來已經進行的投資根本無法提供很高的資本回報率。

Another point to note, we noticed the company has increased current liabilities over the last five years. This is intriguing because if current liabilities hadn't increased to 52% of total assets, this reported ROCE would probably be less than7.1% because total capital employed would be higher.The 7.1% ROCE could be even lower if current liabilities weren't 52% of total assets, because the the formula would show a larger base of total capital employed. Additionally, this high level of current liabilities isn't ideal because it means the company's suppliers (or short-term creditors) are effectively funding a large portion of the business.

需要注意的另一點是,我們注意到該公司的流動負債在過去五年中有所增加。這很有趣,因爲如果流動負債沒有增加到總資產的52%,則報告的投資回報率可能低於7.1%,因爲所使用的總資本會更高。如果流動負債不佔總資產的52%,7.1%的投資回報率可能會更低,因爲該公式將顯示動用總資本的基數更大。此外,如此高的流動負債水平並不理想,因爲這意味着公司的供應商(或短期債權人)實際上正在爲業務的很大一部分提供資金。

The Bottom Line On China Resources Medical Holdings' ROCE

華潤醫療控股投資回報率的底線

Long story short, while China Resources Medical Holdings has been reinvesting its capital, the returns that it's generating haven't increased. And in the last five years, the stock has given away 17% so the market doesn't look too hopeful on these trends strengthening any time soon. Therefore based on the analysis done in this article, we don't think China Resources Medical Holdings has the makings of a multi-bagger.

長話短說,儘管華潤醫療控股一直在對其資本進行再投資,但其產生的回報並沒有增加。在過去的五年中,該股已經下跌了17%,因此市場對這些趨勢在短期內走強似乎並不抱太大希望。因此,根據本文的分析,我們認爲華潤醫療控股不具備多袋裝的實力。

If you'd like to know about the risks facing China Resources Medical Holdings, we've discovered 1 warning sign that you should be aware of.

如果你想了解華潤醫療控股面臨的風險,我們發現了一個你應該注意的警告信號。

If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.

如果你想尋找收益豐厚的穩健公司,可以免費查看這份資產負債表良好且股本回報率可觀的公司名單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論